Related Experiment Video
Updated: Aug 30, 2026

A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments
Published on: November 9, 2017
A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barré syndrome
J Pritchard1, I A Gray, Z R Idrissova
1Department of Clinical Neurosciences, Guy's, King's & St. Thomas' School of Medicine, London, UK.
Abstract:
The authors recruited 19 nonambulant patients with Guillain-Barré syndrome into a pilot, double-blind, randomized, placebo-controlled safety trial of interferon beta 1a (IFN[beta]-1a) (Rebif). Participants received IFN[beta]-1a or placebo subcutaneously three times weekly, 22 microg for the first week and then 44 microg for up to 24 weeks, in addition to IV immunoglobulin (IVIg). IFN[beta] did not have any unexpected interaction with IVIg and there was no significant difference in rate of improvement.
